Home    Back

 47. Buerger disease
 [ 8 clinical trials,    11 drugs（DrugBank: 7 drugs),    3 target genes / 13 target pathways ] 

Searched query = "Buerger disease", "Thromboangiitis obliterans"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02501018November 1, 201726 August 2019Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI)A Prospective, Open Label, Controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) Due to Arteriosclerosis Obliterans (ASO) With a Single-arm Substudy to Assess the Safety and Potential Efficacy of CLBS12 in Patients With CLI Due to Buerger's Disease (BD)Critical Limb Ischemia;Buerger Disease;Thromboangiitis Obliterans;Atherosclerosis ObliteransBiological: CLBS12;Drug: SOCCaladrius Biosciences, Inc.Recruiting20 Years80 YearsAll35Phase 2Japan
2NCT03056742February 20, 201716 December 2017A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers DiseaseA Single Arm, Open Label, Multicentric, Clinical Study Assessing the Efficacy and Safety of Stempeucel® (ex Vivo Cultured Adult Bone Marrow Derived Allogeneic Mesenchymal Stem Cells) in Patients With CLI Due to Buerger's DiseaseCritical Limb Ischemia Due to Buerger's DiseaseBiological: Stempeucel(R)Stempeutics Research Pvt LtdNot recruiting18 Years65 YearsAll0Phase 2India
3JPRN-UMIN0000213742016/03/072 April 2019Ex Vivo Expanded Erythroblast-Transplantation for patient with critical limb ischemiaPeripheral Arterial Disease (PAD) , Buerger disease, and arteritis associated with collagen diseases (Fontaines stage: III and IV)1)Autologous Bone Marrow Collection: 40 to 60 ml of bone marrow is collected from iliaccrest under local anaesthesia 14 days before the implantation.
2)Ex vivo expanded immature erythroblasts from autologous bone marrow cells : All procedures are enforced by exclusive
technical exparts along the approved protocols in GMP-grade Cell Processing Room established in Bioscience Medical Research Center, Niigata University Medical and Dental Hospital. Mononuclear cells separated from the bone marrow are incubated in a suspension culture in the presence of rh Flt-ligand, rh SCF, rh Thrombopoietin, and culture supplements for 7 days to expand myeloid progenitors. Harvested and washed cells are further cultured in the presence of rh SCF, rh IGF-I, rh Erythropoietin, and culture supplements for additional 7 days to expand immature erythroblasts and macrophages. Cultured cells are finally harvested, washed, suspended in 50 ml of autologous platelet rich plasma, and transferred from the bio clean room to bedside.
3)Transplantation of cultured cell: Aliquots of the 50 ml of cell suspension are intramuscularly injected in 100 points of the ischaemic limb. Daily intramuscular injection of 6000 IU of rh erythropoietin in the same loci follows from day 0 for consecutive 5 days.		EVEETA Study GroupRecruiting20years-old80years-oldMale and Female11Not selectedJapan
4NCT01484574January 201226 September 2016A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers DiseaseA Non-randomized, Open Label, Multicentric, Dose Ranging , Phase II Study Assessing the Efficacy and Safety of Intramuscular Administration of Stempeucel - CLI™ (ex Vivo Cultured Adult Bone Marrow Derived Allogeneic Mesenchymal Stem Cells) in Patients With Critical Limb Ischemia Due to Buerger's DiseaseCritical Limb Ischemia;Buerger's DiseaseBiological: Allogeneic Mesenchymal Stem CellsStempeutics Research Pvt LtdNot recruiting18 Years65 YearsBoth90Phase 2India
5JPRN-UMIN0000026712009/12/012 April 2019A study of therapeutic angiogenesis in critical limb ischemia using gelatin hydrogel incorporating basic fibroblast growth factorArteriosclerosis obliterans Buerger's diseaseMuscular injection of gelatin hydrogel incorporating basic fibroblast growth factorKyoto University Graduate School of Medicine Department of Cardiovascular SurgeryNot Recruiting20years-old80years-oldMale and Female10Not selectedJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT01447550January 200929 August 2016Treatment of Thromboangiitis Obliterans (Buerguer's Disease) With BosentanTreatment of Thromboangiitis Obliterans (Buerger's Disease) With BosentanThromboangiitis ObliteransDrug: BosentanHospital Universitario GetafeNot recruiting18 Years65 YearsBoth12N/ASpain
7NCT01302015December 200717 June 2019Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's DiseaseSafety and Efficacy of Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's DiseaseBuerger's DiseaseBiological: RNL-Vascostem®R-BioNot recruiting20 Years80 YearsAll15N/AKorea, Republic of
8JPRN-C0000002002004/12/012 April 2019Therapeutic angiogenesis with acidic gelatin hydrogel microspheres incorporating fibroblast growth factor-2 for critical limb ischemiaArteriosclerosis obliterance Buerger's diseaseIntra-arterial injection of acidic gelatin hydrogel microsphres (3mg)incorporating human recombinant fibroblast growth factor-2 (trafermin, 0.1mg)The University of Tokyo HospitalThe University of Tokyo, Division of Tissue Engineering35years-old85years-oldMale and Female10Not applicableJapan

Back to top